首页> 美国卫生研究院文献>Cancers >Next-Generation Multimodality of Nanomedicine Therapy: Size and Structure Dependence of Folic Acid Conjugated Copolymers Actively Target Cancer Cells in Disabling Cell Division and Inducing Apoptosis
【2h】

Next-Generation Multimodality of Nanomedicine Therapy: Size and Structure Dependence of Folic Acid Conjugated Copolymers Actively Target Cancer Cells in Disabling Cell Division and Inducing Apoptosis

机译:纳米药物治疗的下一代多模式性:叶酸共轭共聚物的大小和结构依赖性在破坏细胞分裂和诱导细胞凋亡中主动靶向癌细胞。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nanomedicine as a multimodality treatment of cancer utilizes the advantages of nanodelivery systems of drugs. They are superior to the clinical administration of different therapeutic agents in several aspects, including simultaneous delivery of drugs to the active site, precise ratio control of the loading drugs and overcoming multidrug resistance. The role of nanopolymer size and structural shape on the internalization process and subsequent intracellular toxicity is limited. Here, the size and shape dependent mechanism of a functionalized copolymer was investigated using folic acid (FA) covalently bonded to the copolymer poly (styrene- -maleic anhydride) (SMA) on its hydrophilic exterior via a biological linker 2,4-diaminobutyric acid (DABA) to target folic acid receptors (FR) overly expressed on cancer cells actively. We recently reported that unloaded FA-DABA-SMA copolymers significantly reduced cancer cell viability, suggesting a secondary therapeutic mechanism of action of the copolymer carrier post-internalization. Here, we investigated the size and shape dependent secondary mechanism of unloaded 350 kDa and 20 kDa FA-DABA-SMA. The 350 kDa and 20 kDa copolymers actively target folic acid receptors (FR) to initialize internationalization, but only the large size and sheet shaped copolymer disables cell division by intracellular disruptions of essential oncogenic proteins including p53, STAT-3 and c-Myc. Furthermore, the 350 kDa FA-DABA-SMA activates early and late apoptotic events in both PANC-1 and MDA-MB-231 cancer cells. These findings indicate that the large size and structural sheet shape of the 350 kDa FA-DABA-SMA copolymer facilitate multimodal tumor targeting mechanisms together with the ability to internalize hydrophobic chemotherapeutics to disable critical oncogenic proteins controlling cell division and to induce apoptosis. The significance of these novel findings reveals copolymer secondary cellular targets and therapeutic actions that extend beyond the direct delivery of chemotherapeutics. This report offers novel therapeutic insight into the intracellular activity of copolymers critically dependent on the size and structural shape of the nanopolymers.
机译:纳米医学作为癌症的一种多模态治疗方法,利用了药物纳米传递系统的优势。在多个方面,它们优于不同治疗剂的临床给药,包括同时将药物输送到活性部位,精确控制装载药物的比例以及克服多药耐药性。纳米聚合物尺寸和结构形状对内化过程和随后的细胞内毒性的作用受到限制。在这里,研究了功能化共聚物的尺寸和形状依赖性机理,使用叶酸(FA)通过生物连接剂2,4-二氨基丁酸共价键合到共聚物聚(苯乙烯-马来酸酐)(SMA)的亲水性外部, (DABA)靶向在癌细胞上过度表达的叶酸受体(FR)。我们最近报道,未负载的FA-DABA-SMA共聚物显着降低了癌细胞的生存能力,表明内在化后共聚物载体作用的次级治疗机制。在这里,我们研究了空载350 kDa和20 kDa FA-DABA-SMA的大小和形状相关的次级机制。 350 kDa和20 kDa的共聚物主动靶向叶酸受体(FR)以初始化国际化,但是只有大尺寸和片状共聚物会通过细胞内破坏包括p53,STAT-3和c-Myc在内的必需致癌蛋白来破坏细胞分裂。此外,350 kDa FA-DABA-SMA激活了PANC-1和MDA-MB-231癌细胞的早期和晚期凋亡事件。这些发现表明,350 kDa FA-DABA-SMA共聚物的大尺寸和结构片状形状促进了多峰肿瘤靶向机制,以及使疏水化学疗法内在化的能力,从而使关键的致癌蛋白无法控制细胞分裂并诱导凋亡。这些新发现的意义揭示了共聚物次级细胞靶标和治疗作用超出了直接输送化学疗法的范围。这份报告提供了新的治疗见解,对共聚物的胞内活性至关重要,而胞内活性主要取决于纳米聚合物的大小和结构形状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号